Stem Cell Selection for Blood Diseases
Trial Summary
What is the purpose of this trial?
Children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (AlloSCT) will have the stem cells selected utilizing α/β CD3+/CD19+ cell depletion. All other treatment is standard of care.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Alpha/Beta Depletion, Alpha/Beta T Cell Depletion, TCR αβ+ T Cell Depletion, α/β CD3+ T-cell and CD19+ B-cell depletion for blood diseases?
Research shows that TCR-alpha/beta and CD19 depletion is effective in engineering grafts for children with acute myeloid leukemia (AML), achieving a 100% primary engraftment rate and a 67% overall survival rate at 2 years. This suggests that the treatment can be a robust method for managing high-risk blood diseases.12345
Is stem cell treatment with TCR-alpha/beta and CD19 depletion safe for humans?
Research shows that TCR-alpha/beta and CD19 depletion in stem cell treatments is generally safe, with low rates of severe complications like graft-versus-host disease (a condition where the donor cells attack the recipient's body) and non-relapse mortality (death not related to the return of the disease).12567
How is the Alpha/Beta Depletion treatment unique for blood diseases?
The Alpha/Beta Depletion treatment is unique because it selectively removes specific immune cells (TCR alpha/beta+ T cells and CD19+ B cells) from donor stem cell grafts, which can help reduce complications like graft-versus-host disease (a condition where donor cells attack the recipient's body) while preserving beneficial cells like natural killer cells. This approach is particularly useful in stem cell transplants from partially matched donors, offering a more targeted and potentially safer alternative to traditional methods.12358
Research Team
Mitchell S Cairo
Principal Investigator
New York Medical College
Eligibility Criteria
This trial is for children and young adults (0-30 years) with various blood diseases, including high-risk acute leukemia, lymphoma, sickle cell disease, and bone marrow failure syndromes. Participants must have adequate organ function and not be pregnant or breastfeeding. They can't join if they've had a recent transplant or uncontrolled infection.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Conditioning
Patients receive full intensity, reduced intensity, or reduced toxicity conditioning based on disease and other factors
Transplantation
Patients undergo α/β T-cell and CD 19+ B cell depleted allogeneic stem cell transplantation
Post-transplant Monitoring
Patients are monitored for engraftment, chimerism, immune reconstitution, GVHD, and QOL
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Alpha/Beta Depletion
Alpha/Beta Depletion is already approved in United States, European Union for the following indications:
- Acute Myeloid Leukemia (AML) in first complete remission undergoing allogeneic HCT from a matched related donor
- Hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional GVHD prophylaxis in patients with AML in first morphologic complete remission (CR1)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mitchell Cairo
Lead Sponsor